TrialOpen forum infectious diseases2026
Immunobridging Analysis of Pemivibart for the Treatment of COVID-19: A Therapeutic Gap for the Immune-Compromised Population Remains.
Anna Holmes et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.